Does Rallies show 13F holders for IDXX?

Yes. Rallies tracks hedge fund and 13F ownership data for IDXX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is IDXX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.

IDXX (IDEXX Laboratories) Stock Analysis - Hedge Fund Holdings

IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of May 20, 2026, IDXX trades at $551.48 with a market cap of $43.05B and a P/E ratio of 40.37. IDXX moved +1.27% today. Year to date, IDXX is -18.86%; over the trailing twelve months it is +7.04%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $693.17. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns IDXX stock?

Hedge funds tracked by Rallies that own IDXX include Polen Capital, Pinebridge Investments, Chilton Investment, Bridgewater Associates, and Maverick Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IDEXX Laboratories.

IDXX Key Metrics

Key financial metrics for IDXX
Metric	Value
Price	$551.48
Market Cap	$43.05B
P/E Ratio	40.37
EPS	$13.69
Dividend Yield	0.00%
52-Week High	$769.98
52-Week Low	$356.14
Volume	435.42K
Avg Volume	0
Revenue (TTM)	$4.45B
Net Income	$1.10B
Gross Margin	62.05%

Top Hedge Funds Holding IDXX

Polen Capital holds 695.81K shares of IDXX, changed -27.56% as of Mar 31, 2026.
Pinebridge Investments holds 49.50K shares of IDXX, changed -43.17% as of Sep 30, 2025.
Chilton Investment holds 15.03K shares of IDXX, changed -0.22% as of Mar 31, 2026.
Bridgewater Associates holds 10.31K shares of IDXX, changed +67.49% as of Mar 31, 2026.
Maverick Capital holds 1.48K shares of IDXX, changed +0.00% as of Dec 31, 2023.

Latest IDXX News

IDEXX jumps after Q1 beat and higher 2026 EPS outlook to $14.45–$14.90 — May 6, 2026
IDEXX Laboratories Beats Quarterly EPS and Revenue Estimates with 15% Pet Segment Growth — May 5, 2026
IDEXX jumps after Q1 beat and raised 2026 revenue, EPS outlook — May 5, 2026
Idexx Laboratories Posts $278.4M Q1 Profit, Boosts Annual Revenue Outlook to $4.68B–$4.76B — May 5, 2026
IDEXX slides 3.5% as traders de-risk ahead of May 5 earnings — Apr 29, 2026

Recent IDXX Insider Trades

Hunt Nimrata sold 1.76K (~$1.12M) on Mar 3, 2026.
MAZELSKY JONATHAN JAY sold 1.28K (~$833.51K) on Feb 26, 2026.
MAZELSKY JONATHAN JAY sold 1.09K (~$713.38K) on Feb 26, 2026.

IDXX Analyst Consensus

7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $693.17.

Common questions about IDXX

Who owns IDXX stock?: Hedge funds tracked by Rallies that own IDXX include Polen Capital, Pinebridge Investments, Chilton Investment, Bridgewater Associates, and Maverick Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for IDEXX Laboratories.
Does Rallies show 13F holders for IDXX?: Yes. Rallies tracks hedge fund and 13F ownership data for IDXX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is IDXX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IDXX. It does not provide personalized investment advice.